COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

5.76%

Increased from previous period

Positive ROE while Medical - Pharmaceuticals median is negative. Peter Lynch would see if the firm holds a competitive advantage in a struggling sector.

Return on Assets (ROA)

2.25%

Increased from previous period

Positive ROA while Medical - Pharmaceuticals median is negative. Philip Fisher would see if the firm has a stronger model than peers.

Return on Capital Employed (ROCE)

6.68%

Increased from previous period

Positive ROCE while Medical - Pharmaceuticals median is negative. Peter Lynch might see a relative advantage over the sector.

Gross Profit Margin

20.10%

Increased from previous period

Gross margin 75-90% of Medical - Pharmaceuticals median of 25.55%. John Neff would look for incremental cost improvements.

Operating Profit Margin

5.37%

Increased from previous period

Margin of 5.37% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if moderate profitability can be leveraged further.

Net Profit Margin

3.65%

Increased from previous period

Net margin of 3.65% while Medical - Pharmaceuticals is zero. Walter Schloss would examine if modest profitability can expand.

Select Chart Metric:

3349.T Profitability Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Return on Equity (ROE)

5.76%

Increased from previous period

Positive ROE while Medical - Pharmaceuticals median is negative. Peter Lynch would see if the firm holds a competitive advantage in a struggling sector.

Return on Assets (ROA)

2.25%

Increased from previous period

Positive ROA while Medical - Pharmaceuticals median is negative. Philip Fisher would see if the firm has a stronger model than peers.

Return on Capital Employed (ROCE)

6.68%

Increased from previous period

Positive ROCE while Medical - Pharmaceuticals median is negative. Peter Lynch might see a relative advantage over the sector.

Gross Profit Margin

20.10%

Increased from previous period

Gross margin 75-90% of Medical - Pharmaceuticals median of 25.55%. John Neff would look for incremental cost improvements.

Operating Profit Margin

5.37%

Increased from previous period

Margin of 5.37% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if moderate profitability can be leveraged further.

Net Profit Margin

3.65%

Increased from previous period

Net margin of 3.65% while Medical - Pharmaceuticals is zero. Walter Schloss would examine if modest profitability can expand.

Select Chart Metric: